Semaglutide vs Retatrutide
How they differ
- FDA status. Semaglutide: FDA-approved as Ozempic, Rybelsus and Wegovy.1,2,3,4 Retatrutide: In clinical trials; not FDA-approved.5,6,7
Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.
Side by side
| Topic | Semaglutide | Retatrutide |
|---|---|---|
| What it is | A GLP-1 receptor agonist. The Wegovy label describes semaglutide as a GLP-1 analogue with 94% sequence similarity to human GLP-1.1 | An investigational agonist of the GIP, GLP-1 and glucagon receptors, developed by Eli Lilly and also known as LY3437943.5,8 |
| FDA status | FDA-approved FDA-approved as Ozempic, Rybelsus and Wegovy1,2,3,4 FDA-approved. Drugs@FDA lists Ozempic (first approved December 5, 2017), Rybelsus (September 20, 2019) and Wegovy (June 4, 2021). The Wegovy label carries a boxed warning about thyroid C-cell tumors seen in rodents.1,2,3,4 | In clinical trials In clinical trials; not FDA-approved5,6,7 Not FDA-approved. FDA states that retatrutide is not a component of an FDA-approved drug and cannot be used in compounding under federal law.7 |
| HHS compounding policy, October 30, 2026 | Not among the six peptides the policy lists.9 | Not among the six peptides the policy lists.9 |
| FDA compounding safety-risk page | Not addressed in this profile’s sources. | Not addressed in this profile’s sources. |
| Kinds of studies cited |
|
|
| Records collected | 140 ClinicalTrials.gov records and 108 PubMed records collected | 8 ClinicalTrials.gov records and 17 PubMed records collected |
| Area of study | ||
| Latest dated events |
|
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Citations
Sources
Numbered markers in the text point here. Each link opens the original public record.
- 1WEGOVY (semaglutide) injection and tablet · SPL version 19 · published 2026-06-30 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026
- 2Drugs@FDA application NDA209637 · original submission status AP · 2017-12-05 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 3Drugs@FDA application NDA213051 · original submission status AP · 2019-09-20 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 4Drugs@FDA application NDA215256 · original submission status AP · 2021-06-04 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 5Retatrutide in Participants With Type 2 Diabetes and Renal Impairment · record history version 25 · last update posted 2026-07-20 ↗
ClinicalTrials.gov · Official source · Source checked July 22, 2026
- 6ClinicalTrials.gov record NCT06297603 · retained source version 2026-11-13:c86dcf0120caf546c9c9fa9df1808025579fcf0e33236ed212dc3df861690ab7 ↗
ClinicalTrials.gov · Official source · Source checked November 14, 2026
- 7FDA’s concerns with unapproved GLP-1 drugs used for weight loss · content current as of October 1, 2026 ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 8Efficacy and safety of retatrutide in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial (2026) · PMID 42250575 ↗
The Lancet · Official source · Source checked November 14, 2026
- 9HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 10Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial (2023) · PMID 37366315 ↗
The New England Journal of Medicine · Official source · Source checked November 14, 2026
- 11Retatrutide for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA (2023) · PMID 37385280 ↗
The Lancet · Official source · Source checked November 14, 2026
- 12ClinicalTrials.gov record NCT05882045 · retained source version 2026-07-30:d21e38ddcccc7ab66ec1bddaa910bf3c7a7a3149a43f4ac27918a9e80f8452da ↗
ClinicalTrials.gov · Official source · Source checked August 14, 2026
- 13ClinicalTrials.gov record NCT05929079 · retained source version 2026-07-30:d0cad2c0ebfa7ce1f2af088a52c397680123509e21999e7837a0b2b517e9ef04 ↗
ClinicalTrials.gov · Official source · Source checked August 14, 2026
- 14ClinicalTrials.gov record NCT06383390 · retained source version 2026-08-24:4bb37a90f79acd41fc8e0a5c8b4745c3c9610a0993eab8f502e836929a21c5ff ↗
ClinicalTrials.gov · Official source · Source checked September 9, 2026
- 15FDA proposes to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list ↗
U.S. Food and Drug Administration · Official source · Source checked July 29, 2026